TolerGenics, a Maryland cellular therapy company, is developing human therapeutics for the treatment of juvenile diabetes, myasthenia gravis and uveitis, three important autoimmune diseases. The core technology makes the immune system "tolerant" in autoimmune diseases where the body mounts a damaging attack on its own tissues. TolerGenics utilizes a novel, patented (US patent #: 5,817,308) technology developed by scientists at the American Red Cross to train the immune system into no longer attacking a specific protein
